Literature DB >> 28497760

The intestinal microbiome and paediatric liver disease.

Daniel H Leung1, Dean Yimlamai2.   

Abstract

The intestinal microbiome has been the intense focus of recent study, but how the microbiota affects connected organs, such as the liver, has not been fully elucidated. The microbiome regulates intestinal permeability and helps to metabolise the human diet into small molecules, thus directly affecting liver health. Several studies have linked intestinal dysbiosis to the severity and progression of liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutrition-associated liver disease, and cystic fibrosis-associated liver disease. However, there is limited information and interpretation with regard to how the microbiome could contribute to liver disease in the paediatric population. Notably, the gut microbiota is distinct at birth and does not establish an adult profile until the third year of life. Clinical research suggests that paediatric liver disease differs in both severity and rate of progression compared with adult forms, suggesting independent mechanisms of pathogenesis. We discuss data linking the intestinal microbiome to liver disease development and therapeutic efforts to modify the microbiome in children.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28497760     DOI: 10.1016/S2468-1253(16)30241-2

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  9 in total

Review 1.  Microbiome diurnal rhythmicity and its impact on host physiology and disease risk.

Authors:  Samuel Philip Nobs; Timur Tuganbaev; Eran Elinav
Journal:  EMBO Rep       Date:  2019-03-15       Impact factor: 8.807

Review 2.  Liver disease in patients with cystic fibrosis.

Authors:  Natasha Kamal; Pallavi Surana; Christopher Koh
Journal:  Curr Opin Gastroenterol       Date:  2018-05       Impact factor: 3.287

3.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

4.  Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis.

Authors:  Hong-Li Li; Lan Lu; Xiao-Shuang Wang; Li-Yue Qin; Ping Wang; Shui-Ping Qiu; Hui Wu; Fei Huang; Bei-Bei Zhang; Hai-Lian Shi; Xiao-Jun Wu
Journal:  Front Cell Infect Microbiol       Date:  2017-10-26       Impact factor: 5.293

Review 5.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

6.  Intestinal IL-17R Signaling Constrains IL-18-Driven Liver Inflammation by the Regulation of Microbiome-Derived Products.

Authors:  Patricia Castillo-Dela Cruz; Alanna G Wanek; Pawan Kumar; Xiaojing An; Waleed Elsegeiny; William Horne; Adam Fitch; Ansen H P Burr; Kathyayini P Gopalakrishna; Kong Chen; Barbara A Methé; Scott W Canna; Timothy W Hand; Jay K Kolls
Journal:  Cell Rep       Date:  2019-11-19       Impact factor: 9.423

Review 7.  Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis.

Authors:  Jiezhong Chen; Luis Vitetta; Jeremy D Henson; Sean Hall
Journal:  Int J Tryptophan Res       Date:  2022-02-07

Review 8.  Numerical analyses of intestinal microbiota by data mining.

Authors:  Toshio Kobayashi; Akira Andoh
Journal:  J Clin Biochem Nutr       Date:  2018-01-11       Impact factor: 3.114

Review 9.  The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.

Authors:  Julio Plaza-Díaz; Patricio Solís-Urra; Fernando Rodríguez-Rodríguez; Jorge Olivares-Arancibia; Miguel Navarro-Oliveros; Francisco Abadía-Molina; Ana I Álvarez-Mercado
Journal:  Int J Mol Sci       Date:  2020-11-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.